Detalles de la búsqueda
1.
Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine.
J Infect Dis
; 219(11): 1799-1803, 2019 05 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30715452
2.
Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.
J Infect Dis
; 214(4): 525-36, 2016 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26908726
3.
Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.
Am J Epidemiol
; 180(6): 599-607, 2014 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25139208
4.
Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years.
Hum Vaccin
; 7(9): 958-65, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21892005
5.
Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine.
Hum Vaccin
; 6(12): 1054-61, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21157180
6.
Long-term persistence of immune response to the AS04-adjuvanted HPV-16/18 vaccine in Chinese girls aged 9-17 years: Results from an 8-9-year follow-up phase III open-label study.
Asia Pac J Clin Oncol
; 16(6): 392-399, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32780946
7.
Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15-25 years: A phase IV randomized comparative study.
EClinicalMedicine
; 23: 100353, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32639485
8.
A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years.
Hum Vaccin Immunother
; 15(7-8): 1970-1979, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31268383
9.
Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine.
Hum Vaccin
; 4(6): 425-34, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18948732
10.
Ten-year immune persistence and safety of the HPV-16/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age.
Cancer Med
; 6(11): 2723-2731, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28984053
11.
Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
Vaccine
; 32(29): 3694-705, 2014 Jun 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-24674663
12.
Comparison of antibody responses to human papillomavirus vaccination as measured by three assays.
Front Oncol
; 3: 328, 2014 Jan 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-24455487
13.
Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.
Hum Vaccin Immunother
; 10(10): 2965-74, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25483632
14.
Investigation of a regulatory agency enquiry into potential porcine circovirus type 1 contamination of the human rotavirus vaccine, Rotarix: approach and outcome.
Hum Vaccin Immunother
; 9(11): 2398-408, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24056737
15.
Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years.
Vaccine
; 27(4): 581-7, 2009 Jan 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-19022320
16.
Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women.
Vaccine
; 26(29-30): 3608-16, 2008 Jul 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-18541349
Resultados
1 -
16
de 16
1
Próxima >
>>